Episode 240 - Inder Kaul - CMO at Draig Therapeutics

In this episode of The BioHub Podcast, Ben sits down with Dr. Inder Kaul, Chief Medical Officer at Draig Therapeutics, to discuss the evolution of neuropsychiatric drug development and what it takes to translate novel neuroscience into meaningful medicines for patients.Inder brings decades of global clinical development experience, most recently playing a key role in the development of Cobenfy at Karuna Therapeutics and Bristol Myers Squibb - one of the most significant advances in schizophrenia treatment in decades.We explore the journey behind Cobenfy, what its success tells us about pursuing new mechanisms in psychiatry, and the lessons Inder has taken into his current role at Draig.The conversation also dives into Draig’s approach to neuropsychiatry, including its Phase 2 AMPA receptor modulator DT-101 for major depressive disorder, the potential of targeting glutamate and GABA pathways, and what the next generation of CNS drug development could look like.A fascinating conversation with someone who has helped take genuinely differentiated neuroscience from clinical development through to approval.